Cargando…

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

BACKGROUND: Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with multiple sclerosis (pwMS) treated with natalizumab (NTZ) and found a short-term efficient humoral response; however, there are no studies assessing the levels of SARS-CoV-2 IgG antibodies in pwMS treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Altieri, Manuela, Capuano, Rocco, Conte, Miriana, Donnarumma, Giovanna, Grimaldi, Elena, Coppola, Nicola, Galdiero, Massimiliano, d’Ambrosio, Alessandro, Tedeschi, Gioacchino, Gallo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853307/ https://www.ncbi.nlm.nih.gov/pubmed/35171373 http://dx.doi.org/10.1007/s10072-022-05940-0

Ejemplares similares

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Spinal cord ischemia complicating BNT162b2 mRNA COVID-19 vaccination
por: Fotiadou, Aggeliki, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
por: Tanzilli, Antonio, et al.
Publicado: (2022)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2
por: Umezawa, Shu, et al.
Publicado: (2022)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus
por: Kang, Minsung, et al.
Publicado: (2023)

Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic
por: Bonavita, Simona, et al.
Publicado: (2020)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Dementia care and COVID-19 pandemic: a necessary digital revolution
por: Cuffaro, Luca, et al.
Publicado: (2020)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

COVID-19 impact on neurology training program in Italy
por: Di Lorenzo, Francesco, et al.
Publicado: (2021)

An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID)
por: Ferrarese, Carlo, et al.
Publicado: (2020)

Stroke and digital technology: a wake-up call from COVID-19 pandemic
por: Iodice, Francesco, et al.
Publicado: (2021)

Psychological consequences of COVID-19 pandemic on people with multiple sclerosis: A meta-analytic study
por: Altieri, Manuela, et al.
Publicado: (2021)

The psychological impact of Covid-19 pandemic on people with Multiple Sclerosis: A meta-analysis
por: Altieri, Manuela, et al.
Publicado: (2022)

The future of neurology after the COVID-19 pandemic according to neurology residents
por: Ercoli, Tommaso, et al.
Publicado: (2022)

Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP)
por: Dubbioso, Raffaele, et al.
Publicado: (2020)

Neurology and the COVID-19 emergency
por: Berardelli, Alfredo, et al.
Publicado: (2020)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2022)

The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority
por: Tassorelli, Cristina, et al.
Publicado: (2021)

Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic
por: Ricciardi, Dario, et al.
Publicado: (2021)

Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals
por: Li, Min, et al.
Publicado: (2022)

Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome
por: Todisco, Vincenzo, et al.
Publicado: (2018)

Humoral and Cellular Immune Responses to SARS–CoV‐2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion
por: Simon, David, et al.
Publicado: (2021)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
por: Haji, Alhan, et al.
Publicado: (2023)

B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab
por: Stefanski, Ana‐Luisa, et al.
Publicado: (2022)

Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS–CoV‐2 in an Unvaccinated Cohort
por: Simon, David, et al.
Publicado: (2022)

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
por: Iannone, Michela, et al.
Publicado: (2021)

Persistent aura-like visual phenomenon as the unique manifestation of COVID-19 post-infectious white matter lesion: A case report
por: Matrone, Federica, et al.
Publicado: (2021)

Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
por: Capuano, Rocco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_317amgi03pu9gld1hi7tjnsqli